Preventing Alzheimer’s
- Recognizing Alzheimer’s disease before it damages the brain enhances changes of successful treatment and increases the quality of life of the patient -
The baseline
•Every year ~10.000.000 new Alzheimer’s casesworldwide
•No easy way of diagnosing early Alzheimer’s
•No effective treatment
The problem
•Research focus on genetic risk factors (<5% ofall cases)
•Research focus on patients with
irreversible brain damage
•Disproportional little focus on
non-genetic risk factors (> 95% of all cases)
The solution
•A simple, cost-effective diagnostic test usingblood samples
•A test using human-relevant biomarkers forprocesses triggered by non-genetic risk factors
•Biomarkers for processes activated before anysignificant irreversible brain damage
Proprietary technology
•Domain:• Biomarker-based in vitro tools for preventive medicine
•Proprietary products for three high impactpathologies:
• Immunosuppression
• Cancer
• Neurodegeneration
Market validation
• ~10.000.000 newcases every yearworldwide
•Worldwide demandfor a simple, cost-effective and non-invasive solution
~10 million new
diagnosis per year
Market size
Delivering a robust pipeline of Alzheimer’s
therapeutics
About 30% accessible for the blood test (33,000 m€)
About 10% accessible for the blood test (340 m€/year)
The product(1) Liquid biopsy Advantages over traditional tissue-specific biopsy- Quick and easy to obtain,- Minimal pain and risk, - Minimally invasive
(2) Enrichment from plasma/serum of circulating
microRNAs
(3) Simple testing device carrying the ToxGenSolutions Alzheimer’s microRNA biomarker profile- Biosensor device for microRNA are available for other diseases,- Easy to use,- Low costs
(4) Read-out
Screening of individuals >60
years of age
Diagnosis, staging, Prognosis
Therapy selection (Response and
follow-up)
Monitoring(Disease evolution following
therapy)
Impact on clinical care
The business
~10 million new
diagnosis per year
€2,600 per sampleEurope
~2.45,000 new diagnosis per year
North America~475,000 new
diagnosis per year
9-10 m€
Full growth potential
Focus segments until 2024
Pricing based on current average costs without
scanning + 20%
Net profit by 2025 (EU+USA)
(Target: 20,000 tests)
Worldwide
single €125,000 fee and 5-7% royalties per year
(~5,000 test per licensee)
~13 m€
Net profit by 2025: (Target: 10 licences)
Net profit by 2030
(Target: 10% of the global market)
400 m€
The financial plan2015 2021 2022 2023 2024 2025 2026
(2)30.11.2015
Raised: €75,000 (Knowledge Transfer Funds preseed loan)
(4)01.01.2018
Raised: €540,000EFRO funding: €356,000
3RsMC ApS: €94,000ToxGenSolutions: €90,000
20202018 201920172016 2027 2028 2029 2030
(1) 22.05.2015
TGS established; Oxfordlaan 70,
Maastricht
(3)21.03.2017
Raised: €25,000 (3RsMC ApS Loan)
(6)01.01.2026
New capital to co-finance new premises
(5)01.01.2020
Raised: €350,000 (12.02.2019)
Target: €4,500,000 (31.12.2019)
Success criteria:- 10% of the global market- Net profit: 400 m€
Success criteria:- Anchored in EU and USA diagnositcs market- Net profit: 20 m€
5 year investment - Increasing capacity
- Scientific personnel € 1,200,000- Equipment and specialized material € 1,600,000- Integration of the product in the biosensor device € 600,000
- Strenghtning outreach to the market- Business development/Commercial personnel: € 700,000- Commercial material/activities € 400,000
Market adoption
Events (Presentations + exhibitions)
• Annual congress on Neurology and Neuroscience
• World Congress on Alzheimers Disease and Dementia
• World Congress on Neurology and Neuroscience
• International Conference on Neurology and Mental Disorders
• Alzheimer’s Disease and Dementia Conference
• European Dementia Conference
• World Congress on Advances and Innovations in Dementia
• International Conference on Neurology and Cognitive Neurosciences
Industrial PartnershipsDiagnostics industry
✓Firalis
✓reMYND
✓ Icometrix
❑ ...
Pharma/Biotech industry
❑ Janssens Pharmaceuticals
❑ Roche
❑ …
CompetitionNon-invasive
Invasive
Dementia
No irreversible
brain damage
Mild cognitive
impairment
CeXGat
Lumipulse® G NeuroAssay(FujiRebio)
Tau-test(Brigham and Women’s Hospital Boston, (USA))
NfL-test(Washington University School of Medicine
(USA) and German Center for Neurodegenerative Diseases, Tübingen (D))
Aβ1-42-test (Ruhr University (D))
Proteome-test(Kings College, London (UK))
IRS-1-test(UCSF Geriatric Research Center, San Francisco (USA))
microRNA-test(University of Otago, Otago (NZ))
Based on genetic risk factors (<5% of the Alzheimer’s cases)
Diagnostic microRNA kit(Amoneta Diagnostics (F))
TGS test
APOE4-test(LabCorp, USA)
A genetic non-diagnostic test
Competive advantages
✓ Test predicting non-genetic Alzheimer’s potential before irreversible brain damage
occurred
✓ Addressing the urgent need of patients organizations, medical staff, society and
industry
✓ Manageable weaknesses and threats
Mild to severe
irreversible brain
damange
No irreversible
brain damange
Top Related